Literature DB >> 25359989

Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice.

Ayline Kübler1, Jeanette Woiterski1, Kai-Erik Witte1, Hans-Jörg Bühring2, Udo F Hartwig3, Martin Ebinger1, Lena Oevermann4, Markus Mezger1, Wolfgang Herr5, Peter Lang1, Rupert Handgretinger1, Christian Münz6, Maya C André7.   

Abstract

Therapeutic natural killer (NK)-cell-mediated alloreactivity toward acute myeloid leukemia has largely been attributed to mismatches between killer immunoglobulin-like receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While adult acute B-cell precursor leukemia (BCP-ALL) appears to be resistant to NK-cell-mediated lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. In this study, we demonstrate in a donor-patient-specific NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate considerable alloreactivity toward pediatric BCP-ALL in vivo. Notably, both adoptively transferred mature KIR(+) NK cells and immature KIR(-) NK cells arising early posttransplantation in humanized NSG mice exerted substantial antileukemic activity. Low-dose and long-term treatment of humanized NSG mice with the DNA-demethylating agent 5-aza-cytidine distinctly enhanced the antitumor response, interestingly without inducing common inhibitory KIR expression but rather by promoting the differentiation of various NK-cell precursor subsets. Collectively, these data indicate that the future design of innovative therapy protocols should consider further exploitation of NK-cell-mediated immune responses for poor prognosis pediatric BCP-ALL patients.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359989     DOI: 10.1182/blood-2014-05-572743

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.

Authors:  S P Koerner; M C André; J S Leibold; P C Kousis; A Kübler; M Pal; S P Haen; H-J Bühring; L Grosse-Hovest; G Jung; H R Salih
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

2.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

3.  Tumor-priming converts NK cells to memory-like NK cells.

Authors:  Marina Pal; Lisa Schwab; Anastasiya Yermakova; Emily M Mace; Rainer Claus; Ann-Christin Krahl; Jeanette Woiterski; Udo F Hartwig; Jordan S Orange; Rupert Handgretinger; Maya C André
Journal:  Oncoimmunology       Date:  2017-04-18       Impact factor: 8.110

Review 4.  Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.

Authors:  Julia Stomper; John Charles Rotondo; Gabriele Greve; Michael Lübbert
Journal:  Leukemia       Date:  2021-05-06       Impact factor: 11.528

5.  NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia.

Authors:  Agnieszka Mizia-Malarz; Grażyna Sobol-Milejska
Journal:  Dis Markers       Date:  2019-01-02       Impact factor: 3.434

6.  Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Authors:  Ebba Sohlberg; Aline Pfefferle; Sandra Andersson; Bettina C Baumann; Eva Hellström-Lindberg; Karl-Johan Malmberg
Journal:  Oncotarget       Date:  2015-10-27

7.  TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.

Authors:  Martin Lelaidier; Yildian Dìaz-Rodriguez; Martine Cordeau; Paulo Cordeiro; Elie Haddad; Sabine Herblot; Michel Duval
Journal:  Oncotarget       Date:  2015-10-06

Review 8.  The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.

Authors:  Miriam Santiago Kimpo; Bernice Oh; Shawn Lee
Journal:  Curr Oncol Rep       Date:  2019-09-10       Impact factor: 5.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.